Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

Por Yamazaki, Naoya, Takenouchi, Tatsuya, Fujimoto, Manabu, Ihn, Hironobu, Uchi, Hiroshi, Inozume, Takashi, Kiyohara, Yoshio, Uhara, Hisashi, Nakagawa, Kazuhiko, Furukawa, Hiroshi, Wada, Hidefumi, Noguchi, Kazuo, Shimamoto, Takashi, Yokota, Kenji
Publicado no Cancer Chemother Pharmacol (2017)

Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients

Por Nonomura, Yumi, Otsuka, Atsushi, Nakashima, Chisa, Seidel, Judith A., Kitoh, Akihiko, Dainichi, Teruki, Nakajima, Saeko, Sawada, Yu, Matsushita, Shigeto, Aoki, Megumi, Takenouchi, Tatsuya, Fujimura, Taku, Hatta, Naohito, Koreeda, Satoshi, Fukushima, Satoshi, Honda, Tetsuya, Kabashima, Kenji
Publicado no Oncoimmunology (2016)

Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma

Por Honda, Yuki, Otsuka, Atsushi, Ono, Sachiko, Yamamoto, Yosuke, Seidel, Judith A., Morita, Satoshi, Hirata, Masahiro, Kataoka, Tatsuki R., Takenouchi, Tatsuya, Fujii, Kazuyasu, Kanekura, Takuro, Okubo, Yuko, Takahashi, Kenzo, Yanagi, Teruki, Hoshina, Daichi, Hata, Hiroo, Abe, Riichiro, Fujimura, Taku, Funakoshi, Takeru, Yoshino, Koji, Masuzawa, Mamiko, Amoh, Yasuyuki, Tanaka, Ryota, Fujisawa, Yasuhiro, Honda, Tetsuya, Kabashima, Kenji
Publicado no Oncoimmunology (2016)